PHARMACOECONOMIC ANALYSIS OF ROSUVASTATIN GENERICS

Abstract

Statins are quite old and one of the most well-studied drug groups. Evidence-based, reliable information on the efficacy and safety of statins from randomized controlled trials is essential. When selecting statins, they take into account such indicators as high efficiency in long-term therapy, safety, and availability. The aim of the research was the pharmacoeconomic analysis of rosuvastatin generics admitted to the Georgian pharmaceutical market. An assortment study of rosuvastatin generics registered in Georgia, taking into account pharmacoeconomic aspects (using the method of cost minimization); Analysis of qualitative/quantitative, local/episodic information. The assortment of rosuvastatin generics admitted to the Georgian pharmaceutical market is quite diverse, 19 names of rosuvastatin generic drugs manufactured by 18 companies are registered, including 2 locally produced; After determining the reference prices for rosuvastatin generics, in the case of a large part of them, the monthly cost varies from 9 to 20 GEL, however, in some cases from 20 to 80 GEL. However, the pharmacoeconomic analysis clearly states that the use of a high dose is more cost-effective.